The Food and Drug Administration Friday issued warning letters to all three duodenoscope manufacturers for failing to comply with a 2015 order to conduct postmarket surveillance studies to determine whether health care facilities are able to properly clean and disinfect the devices. “The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real-world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.” The letters were sent to Olympus, Fujifilm and Pentax, who are expected to submit a plan by March 24 outlining how study milestones will be achieved.

Related News Articles

Headline
The AHA the week of July 8 released its Quality Collective Report, which explores quality, safety and performance improvement strategies and insights from…
Headline
In a new “Safety Speaks” conversation, Harry S. Smith, board chair of Valley Health System and member of the AHA Committee on Governance, discusses how Valley…
Headline
The Centers for Disease Control and Prevention June 25 issued a Health Alert Network Health Advisory about an increased risk of dengue virus infections in the…
Headline
“Safety Speaks” is a new Advancing Health series where hospital and health system leaders share successes from their organizations’ patient safety efforts. In…
Blog
The Meharry School of Global Health is the realization of a promise made by Meharry Medical College almost 150 years ago — a promise born out of the legacy of…
Headline
As part of Community Health Improvement Week June 10-14, the AHA released a video showcasing the impact Indiana University Health's iHEART collaborative has…